IL37 and Guillain-Barre syndrome: This suggests that IL-37 plays some role in mediating post-stroke inflammation based on the significant rise in serum and urine levels.An additional interesting inference noted in GBS patients was that there was a decline in IL-37 levels by four weeks in those who responded to treatment and showed clinical neurological improvement compared to patients who showed a neurological decline and had persistently elevated IL-37 levels [20].